bioAffinity Technologies, Inc. (BIAF)
| Market Cap | 15.91M +178.2% |
| Revenue (ttm) | 6.16M -34.2% |
| Net Income | -14.91M |
| EPS | -8.66 |
| Shares Out | 4.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,330,641 |
| Open | 3.890 |
| Previous Close | 4.000 |
| Day's Range | 3.435 - 4.270 |
| 52-Week Range | 0.693 - 46.530 |
| Beta | 2.43 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Mar 13, 2026 |
About BIAF
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cance... [Read more]
Financial Performance
In 2025, bioAffinity Technologies's revenue was $6.16 million, a decrease of -34.18% compared to the previous year's $9.36 million. Losses were -$14.91 million, 64.9% more than in 2024.
Financial StatementsNews
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies will host a webinar on April 8 with leading pulmonologists who will share their clinical experience with CyPath Lung.
New Case Study: bioAffinity Technologies' CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies' new patient case study demonstrates the benefit of CyPath Lung in physician decision-making and patient outcome.
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth
bioAffinity Technologies Inc (NASDAQ: BIAF) shares are trading sharply higher Friday morning after the company reported full-year 2025 results highlighting strong growth in its flagship CyPath Lung di...
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports financial results for FY 2025, including record revenue and unit sales for the CyPath Lung test for lung cancer.
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies launches 2,000-patient longitudinal study for its CyPath Lung noninvasive diagnostic for lung cancer.
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AAAAI--bioAffinity Technologies presents research at AAAAI related to identifying drug antibody receptors in sputum for two leading asthma therapies.
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BAMC--bioAffinity Technologies announced validation study with BAMC to assess deep suction sputum samples for lung cancer detection with CyPath Lung.
New Case Study Highlights Ability of bioAffinity Technologies' CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--In new case study, CyPath Lung spares elderly woman from an invasive procedure for a suspicious lung nodule discovered on a CT scan.
Clinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case Study
SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies shares a new case study that demonstrates how CyPath® Lung supports clinical decision-making in high-risk patients.
bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies appoints nationally recognized pulmonary and lung cancer authorities to its Medical and Scientific Advisory Board.
bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity's laboratory, Precision Pathology Laboratory Services, maintains accreditation from the College of American Pathologists.
bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #ACS--bioAffinity Technologies will present case studies at NLCRT in which CyPath® Lung identified Stage 1A lung cancer in high-risk patients.
bioAffinity Technologies Reports Third Quarter 2025 Financial Results
SAN ANTONIO--(BUSINESS WIRE)-- #AI--bioAffinity Technologies reports Q3 2025 financial results, achieves 86% increase in CyPath® Lung testing revenue.
bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announced the volume of CyPath® Lung tests processed in October increased by 111% over the 2025 monthly average.
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
SAN ANTONIO--(BUSINESS WIRE)-- #AI--Australian Patent Office accepts bioAffinity Technologies' patent application for its platform technology to assess lung health and predict disease.
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies will present research related to its noninvasive CyPath Lung test for lung cancer at CHEST 2025.
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #AI--The US Patent and Trademark Office will issue BIAF a new patent on its flow cytometry+AI platform that detects lung cancer as early as Stage 1A.
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies received written notice from Nasdaq stating that the Company has regained compliance with continued listing requirements.
WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J. , Oct. 9, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc...
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closed on a $1.8 million registered direct offering of common stock.
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J. , Oct. 8, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc...
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces a $1.8 million registered direct offering of common stock.
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Sales of bioAffinity's CyPath® Lung test for lung cancer reached a new high in Q3 2025, representing a 95% increase over the previous quarter.
WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m
JERSEY CITY, N.J. , Sept. 30, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, I...
bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closes $4.8 million public offering.